PT  - JOURNAL ARTICLE
AU  - Qi Tan
AU  - Rui Min
AU  - Hong Wang
AU  - Wei-Ping Xie
AU  - Zhi-Hui Xu
AU  - Mao Huang
AU  - Wei-Guo Xu
TI  - Immunotherapy using IL-2 potentially reverse disorders of Th1 /Th17 response in patients with MDR-TB
DP  - 2013 Sep 01
TA  - European Respiratory Journal
PG  - P2816
VI  - 42
IP  - Suppl 57
4099  - http://erj.ersjournals.com/content/42/Suppl_57/P2816.short
4100  - http://erj.ersjournals.com/content/42/Suppl_57/P2816.full
SO  - Eur Respir J2013 Sep 01; 42
AB  - Objective: Prevalence of multidrug-resistant tuberculousis(MDR-TB) worldwide today is urgent. Dysregulation of Th1/Th17 was associated with the pathogenesis and the clinical outcome of MDR-TB infection. Adjunctive immunotherapy with IL-2 evidently enhanced the immune response in mouse model of TB infection .This clinical study investigated the therapeutic effects of Recombinant Human Interleukin-2(rhIL-2) co-administrated with optimized antituberculosis chemotherapy.Methods:We examined Th17 cells and Th1 cells by flow cytometry in peripheral blood of 18 healthy subjects(HCs),16 drug-sensitive TB patients(DS-TBs)and 26 MDR-TB patients(13 using optimized antituberculosis chemotherapy,13 using rhIL-2 plus optimized antituberculosis chemotherapy).Results:We found downregulated Th1 and upregulated Th17 expression in MDR-TBs before treatment. After 7-month treatment, patients using rhIL-2 plus chemotherapy showed more remarkble higher Th1 cell expression than that in patients with chemotherapy .All the MDR-TBs after 7-month treatment showed downregulated Th17 cell expression ,the downregulation in patients after rhIL-2 plus chemotherapy was more significant and normalized to that in HCs.Conclusions:These data provided evidence that immunotherapy with rhIL-2 reverse the disorders of Th1 /Th17 activation in MDR-TB infection,which may promote an enhanced antimicrobial response to improve outcomes in MDR-TB patients.